Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic developmentPhase 3 study is supported by previously presented ELAINE-1 and...

New global survey shows misperceptions about lung cancer among the general public LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Only one in five people (22%) disagree with the statement “generally, patients with lung cancer have caused their illness through their lifestyle choices...

Lung Ambition Alliance unveils new initiatives to address lung cancer survival at the World Conference on Lung Cancer New grants program to support local initiatives driven by patient organizations that have the potential to transform patient care  Series of interactive and educational exhibits at the congress to...

Precipio Updates Commercial Pipeline for its ICE-COLD PCR™ Liquid Biopsy Technology Trials underway at five laboratories and two diagnostic equipment companies NEW HAVEN, Conn., June 19, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO),...